Travoprost Intraocular Implant + iStent Infinite
← catalyst calendarNCT06066645 · readout ≤ 284 d
Sponsored by Glaukos Corporation (industry) · GKOS — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
150estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-14 | actual | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glaucoma, Open-Angle
Interventions
- Drug: Travoprost Intraocular Implant — also filed as iDose TR
- Device: iStent infinite
- Other: Sham procedure
Primary outcome
what the primary-completion date above is the date OFchange from baseline in mean diurnal intraocular pressure (IOP)
measured 3 months
Permalink · GKOS's whole pipeline · Catalyst calendar · Every registered study · What changed